### Influenza Immunisation Programme

- Pregnancy,
- Children aged 6 months to under 5 years who have been hospitalised for respiratory illness or have a history of significant respiratory illness,
- Individuals aged 6 months to under 65 years with an eligible medical condition,
- Individuals aged 65 years or older,
- Individuals aged under 18 years living in specified earthquake or flood affected areas in Bay of Plenty, Nelson Marlborough or Canterbury District Health Boards.

### Kidney disease
- Hepatitis B, Hib, influenza, pneumococcal, Tdap, and varicella vaccines

### Liver disease
- Hepatitis A and varicella vaccines

### Meningococcal disease case — contact with
- Meningococcal vaccine

### Needle stick injury — following
- Hepatitis B vaccine

### Non-consensual sexual intercourse — following
- Hepatitis B vaccine

### Pneumococcal disease — increased risk
- Additional pneumococcal vaccines

### Pregnancy
- Influenza and Tdap vaccines in every pregnancy

### Rubella — women of childbearing age who are not immune to rubella
- MMR vaccine

### Solid organ transplantation

#### Prior to solid organ transplantation
- Hib, meningococcal, pneumococcal, Tdap, and varicella vaccines

#### Following solid organ transplantation
- Hepatitis A, hepatitis B, Hib, HPV, influenza, meningococcal, pneumococcal, and Tdap vaccines

#### Tuberculosis — infants and children aged under 5 years at risk of tuberculosis (TB) exposure
- BCG vaccine

---

## Funded vaccines for special groups from 1st July 2017

<table>
<thead>
<tr>
<th>Vaccine</th>
<th>Individuals eligible for funded vaccine</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Haemophilus influenzae type b (Hib) vaccine (Chapter 6#)</strong></td>
<td>• An additional dose (as appropriate) for (re-)immunisation of individuals post-haematopoietic stem cell transplantation; post-chemotherapy; pre- or post-splenectomy; pre- or post-solid organ transplantation; pre- or post-cochlear implant; with functional asplenia; on renal dialysis or a severely immunosuppressive regimen</td>
</tr>
<tr>
<td><strong>Hepatitis A vaccine (Chapter 7#)</strong></td>
<td>• One dose for close contacts of a hepatitis A case</td>
</tr>
<tr>
<td></td>
<td>• Two doses for transplant patients; or children with chronic liver disease</td>
</tr>
<tr>
<td><strong>Hepatitis B vaccine or Hepatitis B vaccine and hepatitis B immunoglobulin (HBIG) (Chapter 8#)</strong></td>
<td>• Infants born to a mother who is hepatitis B surface antigen (HBsAg) positive; household or sexual contacts of a known acute hepatitis B case or hepatitis B carrier; individuals who are HIV-positive; hepatitis C positive; solid organ transplant patients (excluding liver or kidney, refer below); following immunosuppression due to steroid or other immunosuppressive therapy longer than 28 days*; non-consensual sexual intercourse; or needle stick injury (5mcg/0.5mL or 10mcg/1.0mL as appropriate)</td>
</tr>
<tr>
<td></td>
<td>• Children under the age of 18 years who are considered not to have achieved a positive serology and require additional vaccination (5mcg/0.5mL or 10mcg/1.0mL as appropriate)</td>
</tr>
<tr>
<td></td>
<td>• Adults who are on renal dialysis; or who are liver or kidney transplant patients (40mcg/1.0mL)</td>
</tr>
<tr>
<td><strong>Human papillomavirus (HPV) vaccine (Chapter 9#)</strong></td>
<td>• Three doses for individuals aged 9–26 years inclusively post-solid organ transplantation; post-haematopoietic stem cell transplantation; or who are HIV-positive</td>
</tr>
<tr>
<td></td>
<td>• A maximum of four doses for people aged 9–26 years inclusively post-chemotherapy</td>
</tr>
<tr>
<td><strong>Influenza vaccine (Chapter 10# and the Influenza Kit)</strong></td>
<td>• Pregnant women in every pregnancy during vaccination season</td>
</tr>
<tr>
<td></td>
<td>• Children aged 6 months to under 5 years who have been hospitalised for respiratory illness or have a history of significant respiratory illness</td>
</tr>
<tr>
<td></td>
<td>• Individuals aged 65 years and older</td>
</tr>
<tr>
<td></td>
<td>• Individuals aged 6 months to under 65 years with certain medical conditions, as per the Influenza Kit, including individuals pre- or post-splenectomy; or with Down syndrome, cochlear implant, error of metabolism at risk of major metabolic decompensation</td>
</tr>
<tr>
<td></td>
<td>• Individuals aged under 18 years living in the Seddon/Ward and rural Eastern Marlborough region (within the Nelson Marlborough District Health Board) and Kaikoura and Hurunui areas (within the Canterbury District Health Board); or who have been displaced from their homes in Edgecumbe and the surrounding region (Bay of plenty District Health Board)</td>
</tr>
<tr>
<td><strong>Meningococcal conjugate vaccines (MenCCV under 2 years and MCV4-D 2 years or older) (Chapter 12#)</strong></td>
<td>• One dose for a close contacts of meningococcal disease case</td>
</tr>
<tr>
<td></td>
<td>• Two doses for individuals post-haematopoietic stem cell transplantation; or following immunosuppression due to steroid or other immunosuppressive therapy longer than 28 days*</td>
</tr>
<tr>
<td></td>
<td>• Up to three doses plus booster doses (as appropriate) for individuals pre- or post-splenectomy; pre- or post-solid organ transplantation; with functional asplenia; complement deficiency (acquired or inherited); or who are HIV-positive</td>
</tr>
<tr>
<td><strong>Tetanus, diphtheria and pertussis (Tdap) vaccine (Chapter 14#)</strong></td>
<td>• One dose for pregnant women, between gestational weeks 28 and 38 of every pregnancy</td>
</tr>
<tr>
<td></td>
<td>• Up to four additional doses (as appropriate) for (re-)immunisation of individuals post-haematopoietic stem cell transplantation; post-chemotherapy; pre- or post-splenectomy; pre- or post-solid organ transplantation; on renal dialysis or a severely immunosuppressive regimen</td>
</tr>
</tbody>
</table>

* For example chemotherapy regimens to treat cancer, conditioning regimes prior to haematopoietic stem cell transplantation, and treatment of immune mediated inflammatory disease.
<table>
<thead>
<tr>
<th>Vaccine</th>
<th>Individuals eligible for funded vaccine</th>
</tr>
</thead>
</table>
| Pneumococcal conjugate (PCV13) and pneumococcal polysaccharide (23PPV) vaccines (Chapter 15)<sup>a</sup> | **Children aged under 5 years**<sup>UPDATED</sup>  
Cardiac disease with cyanosis or failure; cerebrospinal fluid leak; chronic pulmonary disease, including asthma treated with high-dose corticosteroid therapy; cochlear implant; corticosteroid therapy for more than two weeks and who are on an equivalent daily dosage of prednisone of 2 mg/kg per day or greater, or children who weigh more than 10 kg on a total daily dosage of 20 mg or greater; diabetes; Down syndrome; functional asplenia; HIV-positive; immunosuppressive therapy; intracranial shunt; nephrotic syndrome; pre-or post-splenectomy; pre-term infant born before 28 weeks gestation; primary immune deficiency; post-haematopoietic stem cell transplantation; post-solid organ transplantation; radiation therapy; or renal failure  
**Children aged 5 years or older, and adults**<sup>UPDATED</sup>  
Post-haematopoietic stem cell transplantation; post-chemotherapy; pre- or post-splenectomy; pre- or post-solid organ transplantation; with functional asplenia; cochlear implant; complement deficiency (acquired or inherited); primary immunodeficiency; on renal dialysis or who are HIV-positive  
PCV13:  
- One dose for children aged 18 months to under 18 years who have previously received four doses of PCV10, or  
- Up to an additional four doses (as appropriate) for (re-)immunisation of children and adults  
23PPV:  
- Up to two doses (as appropriate) for children aged 2 years to under 18 years receiving 23PPV vaccine for the first time, or  
- Up to three doses (as appropriate) for individuals aged 18 years or older receiving 23PPV vaccine for the first time |
| BCG vaccine (Bacillus Calmette-Guérin) (Chapter 20)<sup>a</sup> | All public health community BCG Vaccination Clinics and in-hospital vaccinations are postponed until further notice, due to a global shortage of BCG vaccine. |
| Varicella vaccine (Chapter 21)<sup>a</sup> | Two doses for non-immune individuals:  
- Who are HIV-positive with mild or moderate immunosuppression, on the advice of their specialist  
- Prior to elective immunosuppressive therapy that will be longer than 28 days<sup>Ψ</sup>  
- With chronic liver disease who may in future be candidates for transplantation  
- With deteriorating renal function before transplantation  
- Pre-solid organ transplantation  
- Post-haematopoietic stem cell transplantation, on the advice of their specialist  
- Post-chemotherapy, on the advice of their specialist  
- Who are immune competent inpatients exposed to varicella, for post-exposure prophylaxis  
Two doses for individuals with no clinical history of varicella infection or immunisation:  
- With an inborn error of metabolism at risk of major metabolic decompensation  
- Who are a household contact of a paediatric patient who is immunocompromised or undergoing a procedure leading to immune compromise, where the household contact has no clinical history of varicella infection of immunisation  
- Who are a household contact of an adult patient who has no clinical history of varicella and who is severely immunocompromised or undergoing a procedure leading to immune compromise, where the household contact has no clinical history of varicella infection or immunisation |

<sup>a</sup> Refer to recommended chapter in the Immunisation Handbook 2017.  
<sup>Ψ</sup> For example treatment of immune mediated inflammatory disease.